Prostate Cancer Update Think Tank 1

Select Publications

Bolla M et al; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572-8. Abstract

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Carlini P et al. Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analysis of 6 randomized trials. Proc ASCO 2006;Abstract 4642.

D’Amico AV et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 2006;24(25):4190-5. Abstract

D’Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7. Abstract

Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. Rev Urol 2003;5(Suppl 2):42-7. Abstract

Glode LM. The case for adjuvant therapy for prostate cancer. J Urol 2006;176(6 Suppl):30-3. Abstract

Gomella LG. Addressing the needs of the high-risk prostate cancer patient. Rev Urol 2005;7(Suppl 5):18-28. Abstract

Hanks GE et al; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8. Abstract

Kumar S et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019. Abstract

Lawton CA et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800-7. Abstract

MacDonald OK et al. Predicting men at high risk for PSA failure after salvage radiotherapy for rising PSA following prostatectomy. Proc ASCO 2006;Abstract 4570.

Messing EM et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9. Abstract

Miller DC et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98(16):1134-41. Abstract

Peeters ST et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990-6. Abstract

Rosenbaum E et al. Adjuvant weekly docetaxel for high-risk prostate cancer patients following radical prostatectomy. Proc ASCO 2006;Abstract 84.

Stephenson AJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23(28):7005-12. Abstract

Stephenson AJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291(11):1325-32. Abstract

Tangen CM et al. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003;2(1):41-5. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Zeliadt SB et al. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2006:66(2): 395-402. Abstract